Ichnos Capital Raise Key For Glenmark, BEAT Platform A Core Value Driver
Q3 Favipiravir Revenues Dive But Remogliflozin Strong
All eyes are on a fundraising plan by Glenmark’s US innovation spin-out Ichnos, with management signaling that its proprietary BEAT platform will be the biggest value driver rather than any individual pipeline asset. The company's India business rang in a strong Q3, with remogliflozin and combinations expected to emerge as a significant franchise.
